Trial Profile
Toxicological evaluation and antitumoral effect of hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma treatment.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Ethiodized oil (Primary) ; Fluorouracil (Primary) ; Nimotuzumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 01 Sep 2011 New trial record